Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy: Is it possible to limit the duration of the application of amifostine

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL.4, 1999, Pages 23-26

  Peters, Kerstin ^a   Mücke, Ralph ^b   Hamann, Dieter ^b   Ziegler, Peter Georg ^b   Fietkau, Rainer ^b  

^a Klin Poliklin Strahlentherapie U   (Germany)

^b NONE

Author keywords

Amifostine; Carboplatin; Head and neck tumors; Radio chemotherapy

Indexed keywords

AMIFOSTINE; CARBOPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; HEAD TUMOR; HUMAN; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NECK TUMOR; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND FUNCTION; SKIN TEMPERATURE; THROMBOCYTE COUNT;

EID: 0345580771     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bokemeyer C, Hartmann JT, Fels L, et al. Amifostine protects against early cisplatin-induced renal damage and enhances CD34+ cell numbers for PBSC collection. ASCO 16;1997:abstract 166.
2. Borsi JD, Csaki C, Ferencz T, et al. Safety and efficacy of amifostine in children to prevent myelotoxicity of high dose carboplatin: preliminary results of a cooperative phase I-II clinical trial. ASCO 1997;16:abstract 1882.
3. Büntzel J, Küttner K, Russell L, et al. Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. ASCO 1997;16:abstract 1400.
4. Busch M, Schymura B, Dühmke E. Cytoprotection with amifostine in recurrent head and neck cancer. ASCO 1997;16:abstract 1418.
5. Constine LS, Zagars G, Rubin P. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys 1986;12:1505-8.
6. DiPaola R, Goodin S, Rodriguez R. et al. Amifostine and dose intense paclitaxel in patients with advanced malignancies. ASCO 1997;16:abstract 826.
7. Douay L, Hu C, Giarranta M-C, et al. Comparative effects of amifostine on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants. Semin Oncol 1994;21:Suppl 11:16-20.
8. Giglio R, Mickiewicz E, Pradier E, et al. Alternating chemotherapy + radiotherapy with amifostine protection for head and neck cancer. Early stop of a randomized trial. ASCO 1997;16:abstract 1369.
9. Liu T, Liu Y, Zhang Z. Use of radiation with or without WR 2721 in advanced rectal cancer. Cancer 1992;69:2820-5.
10. Mercer V. Anderson H, Habboubi N, et al. A phase III randomised study of carboplatin and amifustine versus carhoplatin and G-CSF in patients with inoperable non-small cell lung cancer. ASCO 1997;16:abstract 1708.
11. Schultze J, Bohuslavizki KH, Kimmig B. Speicheldrüsenprotektion mit Amifostin bei der Strahlentherapie von Kopf-Hals-Tumoren - Erste klinische und szintigraphische Ergebnisse. Radiologe 1997;37:118.
12. Trog D, Füller J, Koscielny S, et al. Can amifostine reduce the toxicity of prolonged 5-fluorouracil continuous infusion and percutanuous radiotherapy in head and neck cancer. J Cancer Res Clin Oncol 1998;Suppl 124:R 53,abstract 12.36.03.
13. Wassemian T. Radiotherapeutic studies with amifostine. Semin Oncol 1994;21:Suppl 11:21-5.